Drug intelligence / Profile preview

SP-201-8

Development stage: Preclinical
Lead developer: Shaman Ventures
Modality: Small Molecules

Overview

SP-201-8 is a small molecule drug candidate developed by Shaman Ventures, currently in preclinical development for the treatment of arthritis and chronic pain. The compound functions by modulating the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor, an ion channel primarily expressed in nociceptive sensory neurons that plays a critical role in the detection and transmission of pain and heat. By modulating TRPV1 activity, SP-201-8 aims to alleviate chronic pain and reduce inflammation associated with arthritic conditions. The drug is part of a pipeline inspired by natural compounds and is designed to provide a targeted approach to pain management.

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on SP-201-8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP-201-8.

Explore the full profile